[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Rossi G, Marchioni A, Romagnani E, Bertolini F, Longo L, Cavazza A, Barbieri F: Primary lung cancer presenting with gastrointestinal tract involvement: clinicopathologic and immunohistochemical features in a series of 18 consecutive cases. J Thorac Oncol; 2007 Feb;2(2):115-20
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lung cancer presenting with gastrointestinal tract involvement: clinicopathologic and immunohistochemical features in a series of 18 consecutive cases.
  • BACKGROUND: Lung cancer initially manifesting as gastrointestinal (GI)-tract metastasis is exceedingly rare, representing a diagnostic challenge and a late-stage disease sign.
  • The clinicopathologic characteristics of the largest series of lung carcinomas initially presenting with GI involvement were described, focusing on differential diagnosis and therapeutic options.
  • METHODS: Eighteen consecutive cases of lung cancer (11 surgical specimens and 7 biopsies) initially diagnosed on GI histologic samples were identified during routine pathologist practice.
  • The small bowel was the most common GI involved site (12 cases), followed by the stomach (four) and large intestine (two).
  • Only half of cases were correctly diagnosed on GI biopsies.
  • Fourteen patients died shortly from disease (mean follow-up, 3 months); two are still alive with multiple metastases, and two patients with the GI tract as the unique site of metastasis underwent pulmonary lobectomy and chemotherapy and are alive without evidence of disease.
  • CONCLUSION: Lung cancer presenting as GI-tract metastasis is probably more frequent than expected, and pathologists should always keep in mind this possibility when dealing with undifferentiated GI carcinoma.
  • Although GI metastasis from lung cancer is associated with dismal outcomes, pulmonary resection coupled with chemotherapy might represent a therapeutic option in selected patients with a solitary GI-tract metastasis.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410025.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Pectasides D, Psyrri A, Pliarchopoulou K, Floros T, Papaxoinis G, Skondra M, Papatsibas G, Macheras A, Athanasas G, Arapantoni-Datioti P, Economopoulos T: Gastric metastases originating from breast cancer: report of 8 cases and review of the literature. Anticancer Res; 2009 Nov;29(11):4759-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric metastases originating from breast cancer: report of 8 cases and review of the literature.
  • BACKGROUND: Breast cancer metastasis to the stomach is rare.
  • It is very important to distinguish a breast cancer metastasis to the stomach from a primary gastric cancer on the basis of clinical, endoscopic, radiological and histopathological features, in order to administer the appropriate treatment.
  • PATIENTS AND METHODS: Eight patients with breast cancer metastasis to the stomach were identified in our database between 1995 and 2008.
  • RESULTS: The median age at initial breast cancer diagnosis was 59.5 years (range 44-75 years), while the median interval between the primary breast cancer and the gastric involvement was 41 months (range 2-82 months).
  • All the patients received chemotherapy and two of them were also treated with hormonal treatment.
  • Two patients underwent surgical intervention, while one patient who had gastric involvement as the only metastatic site will proceed to surgical resection of the stomach.
  • The response rate to chemotherapy was 50% (1 complete response [CR], 3 partial responses [PR]), and the median survival was 11 months (range, 1-44+ months).
  • CONCLUSION: Breast cancer metastasis to the stomach can be differentiated from primary gastric cancer by comparing the biopsies from the gastric metastasis with the original histological slides from the primary breast tumor.
  • Appropriate systemic treatment for metastatic breast carcinoma is the preferred treatment, whereas surgical intervention should be reserved for palliation or may be indicated in cases of solitary resectable gastrointestinal tract metastases.
  • [MeSH-major] Breast Neoplasms / pathology. Stomach Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Female. Humans. Middle Aged


3. Jamali FR, Darwiche SS, El-Kinge N, Tawil A, Soweid AM: Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy. Oncologist; 2007 Apr;12(4):438-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
  • Gastrointestinal stromal tumors (GISTs) represent the most common mesenchymal neoplasms of the GI tract.
  • The optimal management of GISTs has been evolving rapidly over the past 5 years and depends on proper histopathologic and radiologic diagnosis as well as appropriate multidisciplinary medical and surgical treatments.
  • Complete surgical resection of primary localized GIST with negative margins remains the best therapeutic option today.
  • In the setting of locally advanced or metastatic disease, imatinib mesylate has emerged as the initial treatment of choice, administered either as cytoreductive or as definitive treatment.
  • We report on the surgical management of an unusual and clinically significant complication following progression of disease secondary to imatinib resistance.
  • The role of surgical therapy in the management of GIST complications following resistance to imatinib and the integration of surgical and molecular therapy of locally advanced or metastatic GISTs are discussed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / surgery. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Benzamides. Combined Modality Therapy. Disease Progression. Fatal Outcome. Female. Humans. Imatinib Mesylate. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neoplasm Metastasis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470686.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


Advertisement
4. Hoshi A, Tokunaga M, Usui Y, Yamashita H, Sasaki H, Kobayashi Y, Shima M, Miyakita H, Terachi T: [Metastatic small intestinal tumor associated with transitional cell carcinoma: a report of 2 cases and review of cases in Japan]. Hinyokika Kiyo; 2005 Jan;51(1):41-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic small intestinal tumor associated with transitional cell carcinoma: a report of 2 cases and review of cases in Japan].
  • However, metastasis to the gastrointestinal tract is rare.
  • Case 1: A 87-year-old man had a history of bladder tumor (TCC, grade 3, pT2bN0M0) and has transurethral resection of bladder tumor (TUR-BT) three times.
  • As computed tomography (CT) showed abdominal free air, our diagnosis was perforation of gastrointestinal tract.
  • We found the elastic hard tumor in the ileum on the perforated lesion, which showed metastatic TCC in the ileum pathologicaly.
  • CT showed a bladder tumor invaded into the prostate (pT4aN1M0), we performed total cyctectomy and ileal conduit after neo-adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Ileal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Cystectomy. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732341.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 15
  •  go-up   go-down


5. Rodriguez GI, Jones RE, Orenberg EK, Stoltz ML, Brooks DJ: Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors. Clin Cancer Res; 2002 Sep;8(9):2828-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients had metastatic or relapsed cancer of the colon, breast, pancreas, gastrointestinal tract, lung, and other sites.
  • Transient febrile episodes were reported in 82% of patients with drug administration but were easily controlled.
  • Drug-related gastrointestinal events were mild and appeared unrelated to dose.
  • Terminal half-life was 3-4 h, and 23% of the administered drug was recovered in the urine as unchanged drug.
  • On the basis of the time to recovery from neutropenia, the recommended schedule for Phase II studies is one treatment every 2 weeks, at a minimum dose of 270 mg/m(2).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Half-Life. Humans. Infection / etiology. Infusions, Intravenous. Male. Middle Aged. Molecular Structure. Neoplasm Metastasis. Neoplasm Recurrence, Local / drug therapy. Neutropenia / chemically induced. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12231523.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; UCC4EQS7WL / tezacitabine
  •  go-up   go-down


6. Kliche KO, Kubsch K, Raida M, Masri-Zada R, Höffken K: Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients. J Cancer Res Clin Oncol; 2002 Sep;128(9):516-24
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
  • PURPOSE: To study efficacy and tolerability of chronomodulated (CM)-chemotherapy in patients with metastatic or locally advanced tumors of the GI tract.
  • PATIENTS AND METHODS: We treated 79 patients with metastatic or locally advanced colorectal cancer ( n=52), cancer of the pancreas/biliary tract ( n=14), and other malignancies ( n=14) with a total of 592 courses of CM-therapy.
  • Out of the total study population 53/79, i.e., 67.1% had received prior chemotherapy.
  • Most of the patients (77.2%) received sodium-folinate-5-FU-oxaliplatin-CM (SOFOX-CM) as first-line chronomodulated therapy, 20.3% received sodium-folinate-5-FU-irinotecan-CM (SOFIRI-CM), and 2.5% ( n=1) received sodium-folinate-5-FU-gemcitabine-CM (SOFGEM-CM).
  • CM-therapy led to complete response (CR) in 1.3%, partial response (PR) in 15.2%, stable disease (SD) in 32.9%, and progressive disease (PD) in 44.3% of all patients.
  • The median PFS was also 4 months (range, 0-21 months) for those patients receiving SOFOX-CM as first CM-therapy ( n=61), while it was found to be 0 months (range, 0-10 months) for patients ( n=16) receiving SOFIRI-CM as first chronomodulated therapy.
  • CONCLUSIONS: We found CM-therapy to be effective and safe in the treatment of advanced malignancies of the GI tract.
  • Sodium folinate offers superior feasibility and compatibility with cytostatic drugs without drawbacks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Deoxycytidine / analogs & derivatives. Gastrointestinal Neoplasms / drug therapy
  • [MeSH-minor] Biliary Tract Neoplasms / drug therapy. Colorectal Neoplasms / drug therapy. Female. Fluorouracil / administration & dosage. Folic Acid / administration & dosage. Humans. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Pancreatic Neoplasms / drug therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12242517.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; 935E97BOY8 / Folic Acid; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Schmidbauer S, Ladurner R, Jückstock H, Trupka AW, Mussack T, Hallfeldt KK: [Surgical and adjuvant therapy of neuroendocrine tumors of the gastrointestinal tract and their metastases. A retrospective analysis of personal patient group]. Chirurg; 2001 Aug;72(8):945-52
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical and adjuvant therapy of neuroendocrine tumors of the gastrointestinal tract and their metastases. A retrospective analysis of personal patient group].
  • [Transliterated title] Die operative und adjuvante Therapie neuroendokriner Tumoren des Gastrointestinaltrakts und ihrer Metastasen. Eine retrospektive Analyse des eigenen Patientenguts.
  • INTRODUCTION: Carcinoid tumors are the most common neuroendocrine tumors of the gastrointestinal tract.
  • Surgical treatment and prognosis depend on the location of the tumor.
  • METHOD: Between 01.01.1985 and 31.12.1999 25 patients with neuroendocrine tumors of the gastrointestinal tract or their metastases were treated in our institution.
  • RESULTS AND CONCLUSIONS: The most frequent primary sites were the ileum and jejunum (36%), appendix (36%), stomach (12%), pancreas (8%), colon (4%) and bronchus with hepatic metastasis (4%).
  • A malignant carcinoid syndrome was present in 8 patients.
  • Some patients with advanced disease needed some surgery for tumor debulking and resection of metastases.
  • In non-resectable liver metastases hepatic arterial chemotherapy and chemoembolization after implantation of port catheters seem to be very beneficial therapeutic options.
  • A fixed part of the therapeutic regime in progressive disease is adjuvant chemotherapy with 5-fluorouracil and streptozotocin and symptomatic therapy with octreotide.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / surgery. Liver Neoplasms / secondary. Neuroendocrine Tumors / secondary
  • [MeSH-minor] Adult. Aged. Chemoembolization, Therapeutic. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Male. Malignant Carcinoid Syndrome / drug therapy. Malignant Carcinoid Syndrome / surgery. Middle Aged. Octreotide / administration & dosage. Octreotide / adverse effects. Retrospective Studies. Streptozocin / administration & dosage. Streptozocin / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. STREPTOZOTOCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11554141.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5W494URQ81 / Streptozocin; RWM8CCW8GP / Octreotide; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Yang GC, Wang J, Yee HT: Interwoven dendritic processes of follicular dendritic cell sarcoma demonstrated on ultrafast papanicolaou-stained smears: a case report. Acta Cytol; 2006 Sep-Oct;50(5):534-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: We observed novel cytologic features of FDC sarcoma in a liver fine needle aspirate of a 46-year-old man status post surgery and chemotherapy for FDC sarcoma, originating in the gastrointestinal tract with metastases to the liver, pancreas and spleen.
  • CONCLUSION: The ultrastructural features of a web of interwoven, dendritic, cytoplasmic processes of FDC tumor was demonstrated for the first time on cytology.
  • Observation of this feature may allow the diagnosis to be made on cytology prior to histology, immunohistochemistry or electron microscopy.
  • [MeSH-major] Dendritic Cells, Follicular / pathology. Gastrointestinal Neoplasms / pathology. Liver Neoplasms / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Antigens, Surface / analysis. Antigens, Surface / immunology. Antigens, Surface / metabolism. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Biopsy, Needle. Cell Shape. Diagnosis, Differential. Humans. Liver / pathology. Lymph Nodes / pathology. Male. Middle Aged. Papanicolaou Test / methods. Papanicolaou Test / standards. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17017440.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Vithayasai N, Ningsanond V, Niramis R: Wilms' tumor with metastasis to duodenum - the first reported case in Thailand. J Med Assoc Thai; 2000 Sep;83(9):1116-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor with metastasis to duodenum - the first reported case in Thailand.
  • A case of Wilms' tumor with gastrointestinal tract metastasis of the duodenum was documented in a 22 month - old - child.
  • She had been diagnosed with Wilms' tumor stage III, treated surgically and by radiation and chemotherapy about 1 year previously.
  • While she was still on chemotherapy, she developed hematemesis and clinical signs of partial gut obstruction.
  • Gastroscopy and upper gastrointestinal series showed an intraluminal vascular mass in the duodenal bulb and histologically proved to be Wilms' tumor.
  • We believe this is the first report in the world of Wilms' tumor with gastrointestinal tract metastasis.
  • [MeSH-major] Duodenal Neoplasms / secondary. Kidney Neoplasms / pathology. Wilms Tumor / secondary

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11075982.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] THAILAND
  •  go-up   go-down


10. Tsilimparis N, Menenakos C, Rogalla P, Braumann C, Hartmann J: Malignant melanoma metastasis as a cause of small-bowel perforation. Onkologie; 2009 Jun;32(6):356-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma metastasis as a cause of small-bowel perforation.
  • BACKGROUND: Malignant melanoma is a disease with an increasing rate of incidence, currently at 10 cases per 100,000.
  • In most cases, malignant melanoma metastasizes over the lymph vessels to parenchymal organs.
  • Symptomatic metastases are found in the gastrointestinal tract in only about 2% of the patients.
  • CASE REPORT: A 43-year-old patient with a known metastasized malignant melanoma (brain, liver, bones) was admitted to the department of dermatology due to fatigue, headache and unspecified abdominal symptoms.
  • Because of persistent abdominal symptoms, a computed tomography (CT) scan of the abdomen was performed, showing a perforation of the ileum with an abscess on the basis of multiple small-bowel metastases.
  • The postoperative course of the patient was complicated by a subcutaneous wound infection and a prolonged period of convalescence (due to multiple brain metastases).
  • CONCLUSIONS: Novel therapy concepts and medication in the treatment of patients with malignant melanoma have improved life expectancy.
  • [MeSH-major] Intestinal Neoplasms / complications. Intestinal Neoplasms / secondary. Intestinal Perforation / diagnosis. Intestinal Perforation / etiology. Intestine, Small / injuries. Melanoma / diagnosis. Melanoma / secondary. Skin Neoplasms / complications. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19521125.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Reiman T, Butts CA: Upper gastrointestinal bleeding as a metastatic manifestation of breast cancer: a case report and review of the literature. Can J Gastroenterol; 2001 Jan;15(1):67-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper gastrointestinal bleeding as a metastatic manifestation of breast cancer: a case report and review of the literature.
  • CASE PRESENTATION: A 64-year-old woman with known metastatic lobular breast cancer presented with fever, epigastric pain, hematemesis, and melena.
  • A bleeding, ulcerated gastric metastasis was found and was treated with endoscopic therapy, omeprazole, and hormonal therapy.
  • The bleeding was probably precipitated by necrosis of the lesion during chemotherapy.
  • DISCUSSION: Gastrointestinal tract metastases from primary breast carcinoma are present in 14% to 35% of cases in autopsy series, with gastric involvement in 6% to 18% of cases.
  • Recognized much less commonly during life than in autopsy studies, they can occur anywhere in the gut and can mimic virtually any gastrointestinal disorder.
  • Endoscopy and barium studies facilitate diagnosis.
  • Reported cases of bleeding gastric metastases have been treated successfully with various local and systemic modalities.
  • The median survival time of reviewed cases was four months from presentation (with a range of zero to 24 months).
  • CONCLUSIONS: Gastrointestinal metastasis is an underdiagnosed complication of breast cancer.
  • Gastrointestinal bleeding from metastatic breast cancer is an uncommon presentation that is readily diagnosed and that can be treated successfully by endoscopic hemostatic therapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / secondary. Gastrointestinal Hemorrhage / etiology. Stomach Neoplasms / secondary


12. Ji YI, Jung MH: Gastrointestinal bleeding caused by ileal metastasis of a tubal complete mole: a case report. J Womens Health (Larchmt); 2010 Jun;19(6):1217-20
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal bleeding caused by ileal metastasis of a tubal complete mole: a case report.
  • BACKGROUND: Tubal hydatidiform mole is known to be an extremely rare disease, moreover, gastrointestinal metastasis from an ectopic complete mole has never been reported.
  • MATERIALS AND METHODS: A 33-year-old woman presented with gastrointestinal bleeding.
  • The patient received nine cycles of adjuvant methotrexate chemotherapy after small bowel resection and anastomosis.
  • She was been without recurrence 20 months after therapy.
  • DISCUSSION: Gestational trophoblastic diseases in ectopic pregnancy are rare and gastrointestinal tract metastasis is very infrequent.
  • There have been a few case reports of choriocarcinoma presenting gastrointestinal tract metastasis.
  • To our knowledge, this is the first report of molar pregnancy in a Fallopian tube with ileal metastasis.
  • CONCLUSION: Ectopic molar pregnancy with gastrointestinal metastasis carries a high risk of intestinal perforation and uncontrollable gastrointestinal bleeding.
  • Despite its rarity, gastrointestinal metastasis should nevertheless be considered a possible cause for gastrointestinal bleeding in ectopic molar pregnancy patients after elimination of the more common etiologies.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Hydatidiform Mole / secondary. Ileal Neoplasms / secondary. Pregnancy, Tubal

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20392142.001).
  • [ISSN] 1931-843X
  • [Journal-full-title] Journal of women's health (2002)
  • [ISO-abbreviation] J Womens Health (Larchmt)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Seo JB, Im JG, Goo JM, Chung MJ, Kim MY: Atypical pulmonary metastases: spectrum of radiologic findings. Radiographics; 2001 Mar-Apr;21(2):403-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical pulmonary metastases: spectrum of radiologic findings.
  • Typical radiologic findings of a pulmonary metastasis include multiple round variable-sized nodules and diffuse thickening of interstitium.
  • In daily practice, however, atypical radiologic features of metastases are often encountered that make distinction of metastases from other nonmalignant pulmonary diseases difficult.
  • A detailed knowledge of the atypical radiologic features of a pulmonary metastasis with a good understanding of the histopathologic background is essential for correct diagnosis.
  • Squamous cell carcinoma is regarded as the most common cell type of a cavitating metastasis, but metastatic nodules from adenocarcinomas and sarcomas also cavitate occasionally.
  • Calcification can occur in a metastatic sarcoma or adenocarcinoma, which makes differentiation from a benign granuloma or hamartoma difficult.
  • Pneumothorax commonly occurs in metastases from an osteosarcoma.
  • Air-space consolidation is often seen in cases of metastases from gastrointestinal tract malignancies.
  • Even though tumor emboli in pulmonary arteries can be seen at computed tomography, diagnosis is difficult because they are located in small or medium arteries.
  • A common radiologic appearance of an endobronchial metastasis is an atelectasis.
  • In cases of an endobronchial or a solitary pulmonary metastasis, differentiation between bronchogenic carcinoma and metastasis is difficult.
  • Dilated vascular structures within the mass can be seen in metastatic sarcomas.
  • A sterilized metastasis after chemotherapy is radiologically indistinguishable from a residual viable tumor.
  • [MeSH-major] Lung Neoplasms / secondary. Tomography, X-Ray Computed
  • [MeSH-minor] Calcinosis / pathology. Calcinosis / radiography. Diagnosis, Differential. Humans. Lung / pathology. Lung / radiography. Pneumothorax / pathology. Pneumothorax / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11259704.001).
  • [ISSN] 0271-5333
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


14. Hacker U, Lenz G, Brehm G, Müller-Höcker J, Schalhorn A, Hiddemann W: Metastasis of a rectal adenocarcinoma to the thyroid gland: diagnostic and therapeutic implications. Anticancer Res; 2003 Nov-Dec;23(6D):4973-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of a rectal adenocarcinoma to the thyroid gland: diagnostic and therapeutic implications.
  • BACKGROUND: Overt metastasis from solid tumors to the thyroid gland is a rare finding.
  • Only single cases of metastasis from the gastrointestinal tract have been reported.
  • We describe a rare case of metastasis to the thyroid gland from a rectal adenocarcinoma which had been treated by rectum extirpation and a combined radiochemotherapy seven years earlier.
  • Fine-needle aspiration biopsy is the appropriate diagnostic procedure to define the histological diagnosis.
  • Potentially curative resection should be performed if metastasis to the thyroid gland is the only tumor manifestation.
  • Palliative chemotherapy should be considered if additional tumor manifestations are detected.
  • [MeSH-major] Adenocarcinoma / secondary. Rectal Neoplasms / pathology. Thyroid Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14981954.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Kalender M, Sevinc A, Tutar E, Sirikci A, Camci C: Effect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neurofibromatosis type 1: a case report. World J Gastroenterol; 2007 May 14;13(18):2629-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neurofibromatosis type 1: a case report.
  • Gastrointestinal stromal tumor (GIST) represents the most common mesenchymal malignancy of the gastrointestinal (GI) tract.
  • Patients with neurofibromatosis NF type 1 have an increased risk of developing GI tumors including rare types such as GIST.
  • The patient was diagnosed with NF four years ago and his medical history revealed that he was hospitalized 5 times with a provisional diagnosis of massive lower gastrointestinal bleeding.
  • Computerized tomography showed peritoneal implants three months later.
  • However, control computerized tomography revealed liver and omental metastasis.
  • Despite high dosage, the progression of the metastatic lesions continued in the liver and omentum.
  • The patient started oral sunitinib malate (Sutent) Pfizer Inc, New York, NY, USA) 50 mg per day for 4 consecutive weeks, followed by 2 wk off per treatment cycle.
  • The metastatic lesions in the liver and omentum were decreased in size after four courses, suggesting that sunitinib is also an effective treatment modality for metastatic GIST in NF patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Indoles / therapeutic use. Liver Neoplasms / drug therapy. Neurofibromatosis 1 / complications. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2000 Nov;97(11):1385-90 [11215189.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):625-41 [12717247.001]
  • [Cites] Curr Opin Neurol. 2004 Apr;17(2):101-5 [15021234.001]
  • [Cites] Z Gastroenterol. 2004 Oct;42(10):1183-7 [15508060.001]
  • [Cites] Histopathology. 1991 Jul;19(1):1-11 [1916682.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):706-14 [8317611.001]
  • [Cites] Ultrastruct Pathol. 1993 May-Aug;17(3-4):307-14 [8266596.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1998 Sep;10(9):791-4 [9831275.001]
  • [Cites] AJR Am J Roentgenol. 2004 Dec;183(6):1629-36 [15547202.001]
  • [Cites] AJR Am J Roentgenol. 2004 Dec;183(6):1844-6 [15547245.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):90-6 [16330947.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • (PMID = 17552016.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  • [Other-IDs] NLM/ PMC4146829
  •  go-up   go-down


16. Sarkar FH, Adsule S, Li Y, Padhye S: Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem; 2007 Jun;7(6):599-608
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy.
  • For more than a century, inhibition of prostaglandin biosynthesis via inhibition of the fatty acid cyclooxygenase (COX) has been achieved by non-steroidal anti-inflammatory drugs (NSAIDs), which targets both COX-1 and COX-2 and as such could be responsible for causing gastrointestinal (GI) toxicity.
  • COX-2 is an inducible enzyme produced by many cell types in response to multiple stimuli.
  • Recently, COX-2 over-expression has been found in several types of human cancers such as colon, breast, prostate and pancreas and appears to control many cellular processes.
  • Because of its role in carcinogenesis, apoptosis, and angiogenesis, it is an excellent target for developing new drugs with selectivity for prevention and/or treatment of human cancers.
  • Development of selective COX-2 inhibitors has been successfully documented and as such showed less toxicity to GI tract as compared to conventional NSAIDs.
  • However, the long term use of COX-2 selective inhibitors showed cardiovascular toxicity, and thus their utilization for cancer prevention and therapy is currently questionable, suggesting that further development of novel COX-2 selective agents are needed.
  • Several cytokines, reactive oxygen species (ROS) and mediators of inflammatory pathway such as activation of nuclear factor-kappaB (NF-kappaB) and COX-2 leads to an increase in cell proliferation, survival, and inhibition of pro-apoptotic pathway, ultimately resulting in tumor angiogenesis, invasion and metastasis.
  • In addition, we provide further evidence regarding the state of our knowledge toward the development of novel COX-2 targeting agents for the prevention and/or treatment of human cancers especially pancreatic cancer.
  • [MeSH-major] Antineoplastic Agents. Cyclooxygenase 2 Inhibitors / therapeutic use. Neoplasms / drug therapy. Neoplasms / prevention & control
  • [MeSH-minor] Animals. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Cyclooxygenase 2 / chemistry. Humans. Inflammation / pathology. Isoenzymes / chemistry. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / enzymology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17584158.001).
  • [ISSN] 1389-5575
  • [Journal-full-title] Mini reviews in medicinal chemistry
  • [ISO-abbreviation] Mini Rev Med Chem
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01CA101870-03; United States / NCI NIH HHS / CA / SP20CA101936-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Isoenzymes; EC 1.14.99.1 / Cyclooxygenase 2
  • [Number-of-references] 96
  •  go-up   go-down


17. Papantoniou V, Tsiouris S, Koutsikos J, Ptohis N, Lazaris D, Zerva C: Increased serum carbohydrate antigen 19-9 in relapsed ductal breast carcinoma. Hell J Nucl Med; 2006 Jan-Apr;9(1):36-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased serum carbohydrate antigen (CA) 19-9 is a quite uncommon manifestation of breast cancer both on early disease and on relapse.
  • Surgery and histopathology revealed infiltration by breast adenocarcinoma and she was treated with chemotherapy.
  • At that time serum tumor markers, carcinoembryonic antigen (CEA) and CA 15-3 were within normal range.
  • Over the next six months she displayed an increase of serum CEA while serum CA 15-3 remained within normal range.
  • In an attempt to search for a second neoplasm possibly of gastrointestinal (GI) origin, abdominal computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance cholangio-pancreatography (MRCP), endoscopy of the upper GI tract and colonoscopy were performed, as well as measurement of serum CA 19-9.
  • While no indication of a GI neoplasm was detected, she displayed an over 10-fold increase of serum CA 19-9.
  • Axillary lymph node dissection confirmed an extensive metastatic infiltration of these nodes by breast adenocarcinoma.
  • Three months later serum CA 19-9 and CEA became normal.
  • The interest of this case lies on the unexpected high serum CA 19-9 values found in a breast relapsed adenocarcinoma and in the important contribution of SM in diagnosing the axillary lymph node metastatic infiltration.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / secondary. CA-19-9 Antigen / blood. Carcinoma, Ductal / blood. Carcinoma, Ductal / secondary. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Proteins / blood. Radiopharmaceuticals. Recurrence

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617392.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


18. Lai YC, Ni YH, Jou ST, Ho MC, Wu JF, Chen HL, Hu RH, Jeng YM, Chang MH, Lee PH: Post-transplantation lymphoproliferative disorders localizing to the gastrointestinal tract after liver transplantation: report of five pediatric cases. Pediatr Transplant; 2006 May;10(3):390-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-transplantation lymphoproliferative disorders localizing to the gastrointestinal tract after liver transplantation: report of five pediatric cases.
  • Post-transplantation lymphoproliferative disorder (PTLD) is a life-threatening complication of organ transplantation.
  • All five patients had transmural gastrointestinal (GI) PTLD, which occurred mostly in the stomach and duodenum.
  • Treatment included dose reduction of immunosuppressants and anti-CD20 antibody infusion.
  • Chemotherapy, including cyclophosphamide, doxorubicin, vincristine, and prednisolone, was given to three patients.
  • Four patients have survived more than 10 months until now after treatment.
  • The one who was unresponsive to chemotherapy and anti-CD20 antibody had diffuse metastasis and died of systemic candidiasis.
  • In our series, each PTLD involved the GI tract.
  • [MeSH-major] Gastrointestinal Diseases / immunology. Liver Transplantation / adverse effects. Lymphoproliferative Disorders / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16677368.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunosuppressive Agents
  •  go-up   go-down


19. Skírnisdóttir I, Garmo H, Holmberg L: Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer. Gynecol Oncol; 2007 Apr;105(1):166-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer.
  • OBJECTIVE: The aim of this register study was to determine occurrence of non-genital ovarian metastasis detected by gynecologic surgery presented as ovarian neoplasm in Sweden from 1 January 1990 to 31 December 2003.
  • Origin of metastases and time of detection in relation to surgery were recorded.
  • Age at diagnosis, survival for ovarian metastasis compared to ovarian cancer and prognostic factors were evaluated.
  • METHODS: Utilizing the population-based Swedish In-Patient Registry, Cancer Registry and Causes of Death Registry, we identified 255 cases with non-genital tract metastases to the ovaries detected at gynecological surgery.
  • RESULTS: The proportion of ovarian metastases detected at surgery of all ovarian neoplasm increased from 1.7% to 3.0% during the study period.
  • The patients with ovarian metastasis of non-GI origin were younger than patients with primary ovarian cancer.
  • Ovarian metastasis of GI origin preceded primary diagnosis in 51% of patients but for women with disease of non-GI origin the primary diagnosis was made in 18% of patients after surgery.
  • Five-year survival for patients with ovarian metastasis of GI origin was 11% and it was 24% if metastases were of non-GI origin.
  • Five-year survival for women with ovarian metastases from breast cancer was 26%.
  • In a multivariate analysis, GI surgery at primary surgery for ovarian metastasis was unfavorable prognostic factor.
  • Diagnosis of primary disease known before surgery, primary disease of non-GI or unknown origin and operation at university hospital all had favorable prognostic impact for overall survival.
  • CONCLUSIONS: Detection of non-genital ovarian metastasis at gynecologic surgery is associated with poor prognosis, and prognosis is worse in tumors with GI origin and if the primary is not detected prior to surgery.
  • The results indicate that a thorough patient evaluation is very important before surgery for suspected ovarian neoplasm.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Incidence. Middle Aged. Proportional Hazards Models. Registries. Survival Rate. Sweden / epidemiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Gynecol Oncol. 2007 Jul;106(1):276
  • (PMID = 17184826.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Liang KV, Sanderson SO, Nowakowski GS, Arora AS: Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc; 2006 Apr;81(4):511-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic malignant melanoma of the gastrointestinal tract.
  • Malignant melanoma is one of the most common malignancies to metastasize to the gastrointestinal (GI) tract.
  • Metastases to the GI tract can present at the time of primary diagnosis or decades later as the first sign of recurrence.
  • We report 2 cases of malignant melanoma metastatic to the GI tract, followed by a review of the literature.
  • A biopsy specimen of a mucosal fold in a gastric fundus noted during endoscopy was taken and revealed metastatic malignant melanoma, which was resected 1 month later.
  • Three weeks later, the patient was found to have an ulcerated jejunal metastatic melanoma mass, which was also resected.
  • The second case is a 63-year-old man with an ocular melanoma involving the chorold of the left eye that had been diagnosed 4 years previously, which had been excised several times, who presented with anorexia, dizziness, and fatigue.
  • He was found to have cerebellar and stomach metastases.
  • He underwent adjuvant radiation therapy, chemotherapy, and surgical resection of the gastric melanoma metastasis.
  • In patients with a history of melanoma, a high index of suspicion for metastasis must be maintained if they present with seemingly unrelated symptoms.
  • Diagnosis requires careful inspection of the mucosa for metastatic lesions and biopsy with special immunohistochemical stains.
  • Management may include surgical resection, chemotherapy, immunotherapy, observation, or enrollment in clinical trials.
  • [MeSH-major] Choroid Neoplasms / pathology. Jejunal Neoplasms / secondary. Melanoma / secondary. Skin Neoplasms / pathology. Stomach Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Fatal Outcome. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16610571.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Zucker S, Cao J, Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene; 2000 Dec 27;19(56):6642-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
  • Experimental studies performed prior to 1990 led to the widely held belief that matrix metalloproteinases (MMPs) produced by cancer cells are of critical importance in tumor invasion and metastasis.
  • Phase III clinical trials initiated in 1997-98 using marimastat, prinomastat (AG3340), and BAY 12-9566 alone or in combination with standard chemotherapy in patients with advanced cancers (lung, prostate, pancreas, brain, GI tract) have recently been reported; no clinical efficacy was demonstrated.
  • Bayer and Agouron have discontinued their ongoing Phase III drug trials of MMPIs in advanced cancer.
  • In retrospect, the failure of MMPIs to alter disease progression in metastatic cancer might have been anticipated since MMPs appear to be important in early aspects of cancer progression (local invasion and micrometastasis) and may no longer be required once metastases have been established.
  • (2) the use of MMPIs along with chemotherapy;.
  • (3) the measurement of MMPs in tumor tissue and blood as a means of identifying patients who are more likely to respond to MMPI therapy; and (4) identification of biomarkers that reflect activation or inhibition of MMPs in vivo.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Enzyme Inhibitors / therapeutic use. Matrix Metalloproteinase Inhibitors. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic. Drug Design. Drug Evaluation, Preclinical. Humans. Matrix Metalloproteinases / chemistry. Matrix Metalloproteinases / physiology. Mice. Models, Biological. Neoplasm Metastasis. Neovascularization, Pathologic. Stromal Cells / enzymology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426650.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 75
  •  go-up   go-down


22. Song LP, Hou HL, Zhao H, Zheng W, Zhang L, Gao J: [Clinical study of 22 cases of primary gastrointestinal lymphoma]. Ai Zheng; 2004 Jun;23(6):685-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of 22 cases of primary gastrointestinal lymphoma].
  • BACKGROUND & OBJECTIVE: Primary gastrointestinal lymphoma (PGIL) is extranodal non-Hodgkin's lymphoma (NHL) that originates from extra-nodal tissue of gastrointestinal (GI) tract and has specific clinical and pathological features.
  • This study was to report the clinical and pathological features as well as the treatment outcome of this disease.
  • The diagnosis was confirmed histologically.
  • Low-grade marginal zone derived mucosa-associated lymphoid tissue lymphoma (MALT) showed a better prognosis than other pathological types.
  • Of the 16 patients who received treatment attained complete remission (CR), the 3-year and 5-year survival rates were 62.5% (10/16) and 45.5% (5/11), respectively, whereas the 3-year and 5-year survival rates of the 6 non-controlled patients were 0 and 0.
  • For those receiving surgery combined with chemotherapy and radiotherapy (5 cases received adjuvant chemotherapy after surgery, and 1 patient received abdominal irradiation after the surgery), the 3-year and 5-year survival rates were 83.3% (5/6) and 66.7% (2/3), respectively.
  • [MeSH-major] Intestinal Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15191671.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF: Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol; 2000 Oct;7(9):705-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management.
  • Gastrointestinal stromal tumors (GIST) are rare tumors of the gastrointestinal (GI) tract that arise from primitive mesenchymal cells.
  • GISTs occur throughout the GI tract but are usually located in the stomach and small intestine.
  • The most important prognostic factors are size > 5 cm, tumor necrosis, infiltration and metastasis to other sites, mitotic count > 1-5 per 10 high-powered fields, and most recently, mutation in the c-kit gene.
  • Surgical resection remains the mainstay of treatment, as chemotherapy and radiation are ineffective.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Leiomyoma / pathology. Leiomyosarcoma / pathology. Neoplasms, Nerve Tissue / pathology
  • [MeSH-minor] Decision Trees. Humans. Prognosis

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11034250.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 52
  •  go-up   go-down


24. Régnier-Rosencher E, Barrou B, Marcelin AG, Jacobzone-Leveque C, Cadranel J, Leblond V, Francès C: [Primary effusion lymphoma in two kidney transplant recipients]. Ann Dermatol Venereol; 2010 Apr;137(4):285-9
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Lymphome des séreuses chez le transplanté rénal: deux cas.
  • BACKGROUND: Primary effusion lymphoma (PEL) is a highly malignant non-Hodgkin lymphoma associated with Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 infection (KSHV/HHV-8).
  • OBSERVATION: We describe two male kidney transplant recipients, aged 47 and 51 years, followed for Kaposi's sarcoma in skin, lymph nodes, gastrointestinal (GI) tract and lung whose disease was poorly controlled by sirolimus and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Epstein-Barr Virus Infections / etiology. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Immunosuppressive Agents / adverse effects. Kidney Transplantation. Lymphoma, Primary Effusion / etiology. Neoplasms, Multiple Primary / etiology. Postoperative Complications / etiology
  • [MeSH-minor] Digestive System Neoplasms / drug therapy. Digestive System Neoplasms / secondary. Digestive System Neoplasms / virology. Fatal Outcome. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / virology. Humans. Immunocompromised Host. Kidney Failure, Chronic / etiology. Kidney Failure, Chronic / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / virology. Lymphatic Metastasis. Male. Middle Aged. Pleural Effusion, Malignant / cytology. Pleural Effusion, Malignant / virology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / etiology. Sarcoma, Kaposi / virology. Skin Neoplasms / drug therapy. Skin Neoplasms / etiology. Skin Neoplasms / virology. Viral Load

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20417362.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


25. Ayantunde AA, Agrawal A, Parsons SL, Welch NT: Esophagogastric cancers secondary to a breast primary tumor do not require resection. World J Surg; 2007 Aug;31(8):1597-601
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophagogastric cancers secondary to a breast primary tumor do not require resection.
  • BACKGROUND: Breast cancer metastasis to the gastrointestinal tract (GIT) is rare.
  • When it does occur, the upper GIT is more frequently involved, and lobular infiltrating carcinoma apparently has a greater apparent predilection for the GIT than the ductal type does.
  • This study reviewed the clinicopathological features of esophagogastric secondary tumors from breast cancer.
  • PATIENTS AND METHODS: Patients with breast cancer metastases to the upper GIT referred to us for treatment of either esophageal or gastric cancers between November 1997 and November 2004 were identified from our database.
  • RESULTS: Nine patients with mean age of 71 (range: 57-90) years had median time of 6.5 (2.8-32.8) years between primary breast cancer diagnosis and upper GI metastasis.
  • The sites of metastatic lesions included the lower esophagus (2 patients), gastroesophageal junction (1 patient), gastric body (3 patients), and pylorus (3 patients).
  • Treatment included hormonal therapy and stent in 3 patients, hormonal therapy alone in 1 patient, chemotherapy alone in 1 patient, chemotherapy and gastrojejunostomy in 1 patient, dilatation and stent in 1 patient, and palliative care only in 2 patients.
  • The median survival following treatment of these metastases was 20 (range: 2.1-96.6) months.
  • CONCLUSIONS: The onset of nonspecific GIT symptoms in patients with a history of breast carcinoma should prompt the clinician to rule out the possibility of upper GIT metastasis even many years after the original breast cancer.
  • The use of systemic therapy for breast cancer may result in longer survival.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / secondary. Esophageal Neoplasms / secondary. Stomach Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2002 Sep-Oct;88(5):427-9 [12487566.001]
  • [Cites] South Med J. 2003 Jun;96(6):624-5 [12938796.001]
  • [Cites] AJR Am J Roentgenol. 2000 Sep;175(3):795-800 [10954469.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2214-21 [11147591.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Dig Dis. 1968 Oct;13(10):868-73 [5303029.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] Clin Radiol. 1976 Jan;27(1):9-15 [177243.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Eur J Surg Oncol. 1990 Apr;16(2):121-6 [2157608.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10 ):903-13 [1190198.001]
  • [Cites] Dis Esophagus. 2001;14(3-4):247-50 [11869331.001]
  • [Cites] Am J Gastroenterol. 1995 Sep;90(9):1495-9 [7661177.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12(11):886-94 [16177864.001]
  • [Cites] Eur J Radiol. 1983 Nov;3(4):331-8 [6653567.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):130-5 [1568608.001]
  • [Cites] Breast Cancer Res Treat. 1997 Sep;45(2):181-92 [9342443.001]
  • [Cites] Eur J Cancer. 1993;29A(15):2155-7 [8297656.001]
  • [Cites] Mod Pathol. 1993 Sep;6(5):516-20 [8248106.001]
  • (PMID = 17578645.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down






Advertisement